Leerink analyst Geoffrey Porges lowered his price target for Amgen to $192 from $200 after reporting Q4 results that beat consensus estimates for revenue and earnings, but with the company’s guidance for revenue to decline by 4%-8% in 2019 and for EPS to be flat to down, despite a mid-single digit share count decline after its large share buyback in 2018. The analyst reiterates a Market Perform rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.